# Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

> **NCT07652294** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Spyre Therapeutics, Inc.** · enrollment: 645 (estimated)

## Conditions studied

- Ulcerative Colitis
- Inflammatory Bowel Diseases
- Colitis
- Colitis, Ulcerative

## Interventions

- **DRUG:** SPY001
- **DRUG:** SPY002
- **DRUG:** SPY003

## Key facts

- **NCT ID:** NCT07652294
- **Lead sponsor:** Spyre Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-06-08
- **Primary completion:** 2029-03-02
- **Final completion:** 2030-01-03
- **Target enrollment:** 645 (ESTIMATED)
- **Last updated:** 2026-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07652294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07652294, "Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07652294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*